MARIE
Reference number | |
Coordinator | Oxlantic Medical AB |
Funding from Vinnova | SEK 1 879 300 |
Project duration | April 2024 - December 2025 |
Status | Ongoing |
Venture | Swelife - Collaboration project for better health |
Call | Swelife - Collaborative projects for better health autumn 2023 |
Purpose and goal
The aim of the project is to carry out two clinical studies on Oxlantic´s product MARIE. MARIE is the world´s first wireless and wearable capnograph, i.e. a device that measures CO2 in the patient´s exhaled air. The main goal of the project is to create a clinically relevant product and to get there scientific studies are needed in the intended environment. Carrying out these studies within ambulance healthcare, provides the opportunity to scientifically evaluate MARIE regarding function, performance and handling in an environment that is also considered one of the most demanding.
Expected effects and result
The user study in 2023 shows that MARIE will be important for both patients and intra- and pre-hospital healthcare in the form of reduced patient suffering and optimized resource utilization for healthcare. Summarized in the following statement : "MARIE has potential to become a game changer for at least; Home care patient with lung diseases COPD patients in need of extra oxygen Sepsis patients and intoxications" MARIE can thus contribute to equal care. MARIE also reduces waste by a factor of 5, results will be published by the responsible researcher in a peer-reviewed journal.
Planned approach and implementation
Step 1. Technical verification of MARIE in a clinical setting: Measurements on 25 healthy subjects who are allowed to travel in an ambulance. Measurements take place while driving under conditions similar to ordinary ambulance missions. Publication in a peer-reviewed journal. Step 2. Clinical study focusing on the use of MARIE in an ambulance: Measurements on 200 patients. Measurements take place while traveling during regular ambulance missions. Publication in a peer-reviewed journal.